Navigation Links
Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
Date:9/17/2012

CARLSBAD, Calif., Sept. 17, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE - News) today announced that the company has entered into a Master Development Agreement with Bristol-Myers Squibb Company (NYSE: BMY) for current and future companion diagnostics projects. The current agreement constitutes the second collaboration between the two companies and represents another step in Life Technologies' strategy to develop its diagnostic business through internal development, partnerships and select acquisitions.  

The agreement covers an initial project for oncology and provides for a long-term partnership across a potentially broad range of Life instrument platforms and a wide range of therapeutic areas.

"The pharmaceutical industry is increasingly turning its focus to discovering and delivering targeted, personalized medications," said Ronnie Andrews, president of medical sciences at Life Technologies. "As more and more targeted drugs come onto the market in the next decade, there will be a growing need for diagnostics that can help predict which patients will benefit from which drugs.

"For oncology alone, hundreds of agents are currently in clinical trials," said Andrews, "and we see strong market opportunity in the robust expansion this will mean for the companion diagnostics space."

Life Technologies possesses a breadth of platforms that can be leveraged in the development of new diagnostics. These platforms span both genetic and proteomic analysis, including next-generation sequencing, Sanger sequencing, qPCR, flow cytometry and immuno-histochemistry. In addition, the company recently announced that its Ion Torrent Personal Genome Machine (PGM™) would be developed for proteomics capabilities.

"Life is uniquely positioned to provide pharma a flexible, cost effective means to manage the evolution of the companion diagnostic assay through the drug development process," said Andrews.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Technologies Begins Shipping Ion Proton System
2. Terso Solutions partners with Champion Medical Technologies to offer fully automated tracking of Tissue and Implantable Devices
3. Medisafe 1 Technologies Anticipates a Special Dividend of $0.01 (One Cent) to Each Shareholder of One Common Stock pending the $7MM Perpetual License Sale of Technology Rights
4. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
5. Agricultural Biotechnology: Emerging Technologies and Global Markets
6. Drug Discovery Technologies, BCC Research
7. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
8. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
9. Global E-Clinical Trial Technologies Industry
10. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
11. Antifungal Drugs: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced ... was ranked as the best intraoral camera on DentalCompare,s ... the #2 spot overall. The #1 product was the ... the MouthWatch intraoral camera was "…incredibly popular because it is ... camera has a small sticker price, it doesn,t sacrifice quality ...
(Date:1/23/2017)... YORK , Jan. 23, 2017  Delcath Systems, ... Company focused on the treatment of primary and metastatic ... , Ph.D., MSN, CRNP, President and Chief Executive Officer ... NobleCon13 - Noble Capital Markets, Thirteenth Annual Investor Conference ... Boca Raton, Florida , on Tuesday, January ...
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute Medical,s ... high risk for acute kidney injury (AKI) after ... globally-recognized care guidelines significantly improved outcomes ... AKI more than 33 percent, according to a ... journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 2017 , ... The American Academy of Thermology ... healthcare training and clinical application of medical infrared imaging, has announced the dates ... Courses for Technicians, respectively. , For the first time the AAT is offering ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers of all-natural ... USDA National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... and handling systems to complement our current rigorous food-safety management systems,” said Yishu ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology ... care and gynecological services for women of all ages. The staff ... wide variety of reproductive services from routine health screenings to diagnosing and treating ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Life Under ... and depression from an early age. “Life Under Blankets” is the creation of published ... of Illinois, Circle Campus in Chicago. She went on to pursue a master’s degree ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
Breaking Medicine News(10 mins):